Cholecalciferol is named as an intervention in 4 current clinical trials in our China register. 3 are recruiting patients now. All registered phases are Not applicable. The sponsor with the most trials is Huazhong University of Science and Technology (2). The most-studied condition is Diabetes Mellitus, Type 2.
| Study | Phase | Status | Lead sponsor | Registers |
|---|---|---|---|---|
|
Vitamin D Treat-to-Target Strategy for Children With Overactive Bladder-Wet
NCT06201013 · ClinicalTrials.gov ↗ · Urinary Bladder, Overactive, Overactive Bladder, Urinary Incontinence, Urge
|
Not applicable | Recruiting | Children's Hospital of Chongqing Medical University | China |
|
Effects of Vitamin D and Prebiotic Supplementation on Glucose Control During Pregnancy
NCT06553729 · ClinicalTrials.gov ↗ · Glucose Intolerance During Pregnancy
|
Not applicable | Recruiting | Huazhong University of Science and Technology | China |
|
Effects of Vitamin D3 and Yeast Beta-Glucan Supplementation on Glycemic Control and Cardiovascular Disease Risk in Patients With Type 2 Diabetes
NCT06861062 · ClinicalTrials.gov ↗ · Diabetes Mellitus, Type 2
|
Not applicable | Recruiting | Huazhong University of Science and Technology | China |
|
Effects of Cofrogliptin on Beta-Cell Function in LADA Patients
NCT07460336 · ClinicalTrials.gov ↗ · Latent Autoimmune Diabetes in Adults (LADA)
|
Not applicable | Not yet open | Second Xiangya Hospital of Central South University | China |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
The same active substance in our other registers, matched by its exact name. Each entry links to the register record it comes from.
8 single-substance products containing Cholecalciferol on the HPRA medicines list.
No entry for Cholecalciferol in the EMA, FDA or German BfArM shortage lists we track.
| Lead sponsor | Trials |
|---|---|
| Huazhong University of Science and Technology | 2 |
| Children's Hospital of Chongqing Medical University | 1 |
| Second Xiangya Hospital of Central South University | 1 |
| Register | Trials | Recruiting |
|---|---|---|
| Clinical trials in China | 4 | 3 |
A trial with sites in more than one country appears in each of those registers.
4 current trials in our China register name Cholecalciferol (also registered as Vitamin D3) as a drug or biological intervention, as of the registry sync on 25 September 2026. Completed and withdrawn studies are not counted.
Yes. 3 of the 4 trials are recruiting: 3 with sites in China. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
Huazhong University of Science and Technology (2), Children's Hospital of Chongqing Medical University (1) and Second Xiangya Hospital of Central South University (1). The number in brackets is how many trials each organisation leads.
Yes. The HPRA medicines list includes 8 single-substance products containing Cholecalciferol, for example THORENS 10 000 I.U. /ml oral drops, solution (Galen Pharma Ireland Limited). A licence does not mean a product is currently marketed or reimbursed; see each product's record.
Not in the lists we track: Cholecalciferol has no entry in the EMA, FDA or German BfArM shortage registers as of their latest sync.
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how Cholecalciferol works or whether it is effective, and it is not medical advice.
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Cholecalciferol works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Cholecalciferol (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 25 Sep 2026.